$BHC BUYS. Good time for pharma!
Key Stats:
Technical Indicators:
1️⃣ 50-Day and 200-Day Moving Average Crossover: BHC is trending above its 200-day moving average, showing long-term bullish momentum.
2️⃣ RSI Neutral : No signs of overbought territory, providing room for further upside without a pullback.
3️⃣ Strong Support Zone: Key support held firmly, suggesting bulls are defending this level.
Fundamental Indicators:
1️⃣ Valuation Play: BHC is undervalued relative to its industry, despite consistent revenues of 11.82B annually. The EV/EBITDA ratio of 8.1 confirms a bargain price.
2️⃣ Operational Efficiency: EBITDA margins at 34.5% and an operating cash flow of 1.01B indicate strong cash-generating ability, even under high debt loads.
3️⃣ Catalyst Potential: Patent dispute resolutions and potential drug approvals could act as significant tailwinds for revenue growth and investor sentiment.
Potential Path to Profit:
1️⃣ Lowest Risk: Buy shares outright at current levels.
Disclaimer: We are not a brokerage or investment firm. This is not financial advice. All sales are final.
- Market Cap: 4.4B
- Revenue (TTM): 11.82B
- EBITDA Margi
- Debt: 29.05B (High, but manageable with recent restructuring efforts)
Technical Indicators:
1️⃣ 50-Day and 200-Day Moving Average Crossover: BHC is trending above its 200-day moving average, showing long-term bullish momentum.
2️⃣ RSI Neutral : No signs of overbought territory, providing room for further upside without a pullback.
3️⃣ Strong Support Zone: Key support held firmly, suggesting bulls are defending this level.
Fundamental Indicators:
1️⃣ Valuation Play: BHC is undervalued relative to its industry, despite consistent revenues of 11.82B annually. The EV/EBITDA ratio of 8.1 confirms a bargain price.
2️⃣ Operational Efficiency: EBITDA margins at 34.5% and an operating cash flow of 1.01B indicate strong cash-generating ability, even under high debt loads.
3️⃣ Catalyst Potential: Patent dispute resolutions and potential drug approvals could act as significant tailwinds for revenue growth and investor sentiment.
Potential Path to Profit:
1️⃣ Lowest Risk: Buy shares outright at current levels.
Disclaimer: We are not a brokerage or investment firm. This is not financial advice. All sales are final.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.